IRIS
MILANI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.829
AS - Asia 3.241
EU - Europa 2.576
SA - Sud America 511
Continente sconosciuto - Info sul continente non disponibili 265
AF - Africa 190
OC - Oceania 9
Totale 12.621
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.569
CN - Cina 1.109
SG - Singapore 856
IE - Irlanda 665
HK - Hong Kong 432
IT - Italia 414
VN - Vietnam 371
BR - Brasile 368
RU - Federazione Russa 341
DE - Germania 274
FI - Finlandia 215
FR - Francia 170
GB - Regno Unito 136
ZA - Sudafrica 129
CA - Canada 118
IN - India 105
BD - Bangladesh 86
UA - Ucraina 66
SE - Svezia 65
MX - Messico 41
ES - Italia 40
JP - Giappone 39
PL - Polonia 39
AR - Argentina 37
NL - Olanda 31
IQ - Iraq 30
CO - Colombia 28
TR - Turchia 26
AT - Austria 25
IL - Israele 23
PK - Pakistan 23
ID - Indonesia 19
CR - Costa Rica 18
EC - Ecuador 18
SA - Arabia Saudita 17
VE - Venezuela 17
CL - Cile 16
MA - Marocco 13
PH - Filippine 13
AL - Albania 12
JM - Giamaica 12
LT - Lituania 12
NI - Nicaragua 12
GP - Guadalupe 11
BE - Belgio 10
EG - Egitto 10
AU - Australia 9
GR - Grecia 9
HN - Honduras 9
MY - Malesia 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
DK - Danimarca 8
IR - Iran 8
PY - Paraguay 8
TN - Tunisia 8
CZ - Repubblica Ceca 7
AZ - Azerbaigian 6
BO - Bolivia 6
CW - ???statistics.table.value.countryCode.CW??? 6
PE - Perù 6
PR - Porto Rico 6
PT - Portogallo 6
SV - El Salvador 6
BG - Bulgaria 5
ET - Etiopia 5
GT - Guatemala 5
KZ - Kazakistan 5
SC - Seychelles 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
CH - Svizzera 4
DZ - Algeria 4
EE - Estonia 4
JO - Giordania 4
KE - Kenya 4
KG - Kirghizistan 4
LV - Lettonia 4
MU - Mauritius 4
AM - Armenia 3
BS - Bahamas 3
KH - Cambogia 3
KR - Corea 3
LB - Libano 3
NP - Nepal 3
RO - Romania 3
BB - Barbados 2
EU - Europa 2
HR - Croazia 2
HT - Haiti 2
KW - Kuwait 2
LU - Lussemburgo 2
MN - Mongolia 2
NG - Nigeria 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
Totale 12.334
Salva come PNG Salva come JPEG
Città #
Dublin 665
San Jose 656
Chandler 522
Ashburn 508
Singapore 453
Hong Kong 419
Dallas 393
Council Bluffs 378
Beijing 279
Boardman 175
Los Angeles 155
Nanjing 143
Ho Chi Minh City 135
Helsinki 131
Lauterbourg 124
Johannesburg 121
Jacksonville 108
Princeton 102
New York 99
Lawrence 93
Hanoi 90
Medford 84
Munich 84
Wilmington 74
Santa Clara 67
Pavia 65
Nanchang 60
Buffalo 55
Redondo Beach 55
Shanghai 54
Milan 52
Moscow 43
Shenyang 39
Hebei 38
Montreal 38
São Paulo 37
Changsha 35
Ann Arbor 34
Orem 34
Tokyo 34
Jiaxing 32
Piscataway 32
Turku 32
Chicago 31
Atlanta 30
North Bergen 29
Warsaw 29
Frankfurt am Main 28
Tianjin 28
Denver 27
Rome 27
Chennai 26
Norwalk 26
Nuremberg 26
London 25
Da Nang 23
Phoenix 23
Columbus 22
Houston 22
San Francisco 22
Seattle 22
Brooklyn 21
Hangzhou 21
Stockholm 20
Toronto 20
Washington 20
Haiphong 19
Falkenstein 17
Mexico City 17
Charlotte 16
Naples 16
Guangzhou 15
Poplar 15
Woodbridge 15
Brasília 14
Pune 14
The Dalles 14
Amsterdam 13
Manchester 13
Rio de Janeiro 13
Ankara 12
Boston 12
Managua 12
Palermo 12
Vienna 12
Baghdad 11
Induno Olona 11
Tirana 11
Turin 11
Brussels 10
Florence 10
San José 10
Dhaka 9
Fairfield 9
Hyderabad 9
Medellín 9
Zhengzhou 9
Biên Hòa 8
Cairo 8
Kingston 8
Totale 7.809
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 231
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 169
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 151
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 149
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 140
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 138
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 138
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 137
A patient with AL amyloidosis with negative free light chain results 136
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 136
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 135
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 134
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 133
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 133
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 133
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 132
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 130
A practical approach to the diagnosis of systemic amyloidoses 127
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 127
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 125
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 125
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 122
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 122
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 122
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 122
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 121
Prognostication of survival and progression to dialysis in AA amyloidosis 120
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 118
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 118
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 116
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 115
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 115
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 115
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 112
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 112
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 112
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 111
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 111
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 111
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis 111
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 110
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 110
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy 107
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 106
A case of monoclonal gammopathy of renal significance 105
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 104
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 103
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 103
Development and Validation of Staging Systems for AA Amyloidosis 102
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 101
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 101
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 101
The lung in amyloidosis 100
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 98
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 98
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 98
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 97
La rilevanza diagnostica e prognostica del peptide natriuretico di tipo B (BNP) e del suo frammento N terminale (NT-proBNP) nei pazienti con amiloidosi AL e insufficienza renale 96
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 96
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 95
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 95
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 93
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 92
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 90
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 90
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 89
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 86
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts 86
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 86
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 85
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis 85
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 84
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 83
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 83
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 81
Attitudes about when and how to treat patients with AL amyloidosis: an international survey 81
Management of AL amyloidosis in 2020 81
HeLLePhant: A phantom mimicking non-small cell lung cancer for texture analysis in CT images 80
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 80
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 80
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 79
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions 79
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. 79
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 79
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 77
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 76
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 76
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 76
The use of mass spectrometry for the diagnosis of plasma cell dyscrasias: focus on light chain (AL) amyloidosis patterns. 76
A powerful oral triplet for AL amyloidosis 75
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis 70
Predicting survival in light chain amyloidosis 70
Management of AL amyloidosis in 2020 70
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 69
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance 69
Rethinking the Role of Co-morbidities in Transthyretin Cardiac Amyloidosis: Cinderella or Princess? The Case of Anemia and Iron Deficiency 68
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis 66
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 66
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 65
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma 65
Totale 10.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.744
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.744
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022394 0 0 0 0 12 6 6 33 24 21 54 238
2022/20231.570 166 141 20 87 110 135 14 83 753 11 33 17
2023/2024678 81 139 32 51 61 135 17 37 6 25 49 45
2024/20251.899 49 123 32 49 22 159 131 90 473 94 234 443
2025/20265.242 341 330 464 651 760 213 896 282 507 358 185 255
2026/20271.736 217 281 332 616 290 0 0 0 0 0 0 0
Totale 12.621